6BI0
Trastuzumab Fab N158A, D185A, K190A (Light Chain) Triple Mutant.
Experimental procedure
| Experimental method | SINGLE WAVELENGTH |
| Source type | SYNCHROTRON |
| Source details | ALS BEAMLINE 5.0.3 |
| Synchrotron site | ALS |
| Beamline | 5.0.3 |
| Temperature [K] | 100 |
| Detector technology | CCD |
| Collection date | 2017-05-02 |
| Detector | ADSC QUANTUM 315r |
| Wavelength(s) | 0.97648 |
| Spacegroup name | P 1 |
| Unit cell lengths | 38.501, 79.561, 85.511 |
| Unit cell angles | 113.00, 93.18, 102.13 |
Refinement procedure
| Resolution | 44.112 - 2.057 |
| R-factor | 0.2002 |
| Rwork | 0.199 |
| R-free | 0.22950 |
| Structure solution method | MOLECULAR REPLACEMENT |
| Starting model (for MR) | 1n8z |
| RMSD bond length | 0.003 |
| RMSD bond angle | 0.765 |
| Data reduction software | HKL-2000 |
| Data scaling software | SCALEPACK |
| Phasing software | PHASER |
| Refinement software | PHENIX ((1.10.1_2155: ???)) |
Data quality characteristics
| Overall | Outer shell | |
| Low resolution limit [Å] | 50.000 | 2.120 |
| High resolution limit [Å] | 2.050 | 2.050 |
| Rmerge | 0.077 | 0.475 |
| Rmeas | 0.101 | 0.616 |
| Rpim | 0.064 | 0.388 |
| Number of reflections | 51673 | 3475 |
| <I/σ(I)> | 10.2 | 1.25 |
| Completeness [%] | 92.0 | 61.5 |
| Redundancy | 2.3 | 1.9 |
| CC(1/2) | 0.695 |
Crystallization Conditions
| crystal ID | method | pH | temperature | details |
| 1 | VAPOR DIFFUSION, SITTING DROP | 7 | 277 | 100 mM Tris-HCl, pH 7.0, 20% PEGMME 2000 |






